$0.18
1.71% yesterday
Nasdaq, May 20, 10:18 pm CET
ISIN
US9290331084
Symbol
VOR
Sector
Industry

Vor Biopharma Inc Stock price

$0.18
-0.51 73.99% 1M
-0.62 77.54% 6M
-0.93 83.92% YTD
-1.56 89.74% 1Y
-4.31 96.02% 3Y
-17.82 99.01% 5Y
-17.82 99.01% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 1.71%
ISIN
US9290331084
Symbol
VOR
Sector
Industry

Key metrics

Market capitalization $22.31m
Enterprise Value $-6.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.07
P/B ratio (TTM) P/B ratio 0.34
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-122.15m
Free Cash Flow (TTM) Free Cash Flow $-100.61m
Cash position $60.04m
EPS (TTM) EPS $-1.51
P/E forward negative
Short interest 2.44%
Show more

Is Vor Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vor Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Vor Biopharma Inc forecast:

6x Hold
100%

Analyst Opinions

6 Analysts have issued a Vor Biopharma Inc forecast:

Hold
100%

Financial data from Vor Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 3.49 3.49
32% 32%
-
-3.49 -3.49
32% 32%
-
- Selling and Administrative Expenses 19 19
7% 7%
-
- Research and Development Expense 96 96
1% 1%
-
-119 -119
3% 3%
-
- Depreciation and Amortization 3.49 3.49
32% 32%
-
EBIT (Operating Income) EBIT -122 -122
5% 5%
-
Net Profit -119 -119
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vor Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vor Biopharma Inc Stock News

Neutral
GlobeNewsWire
13 days ago
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing b...
Neutral
GlobeNewsWire
2 months ago
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cel...
Neutral
GlobeNewsWire
3 months ago
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. ...
More Vor Biopharma Inc News

Company Profile

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Bob Ang
Employees 159
Founded 2015
Website www.vorbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today